BACKGROUND: In developed countries, global developmental disorders are encounter- ed in approximately 1% of all children. The causes are manifold, and no exogenous cause can be identified in about half of the affected children. The parallel investi- gation of the coding sequences of all genes of the affected individual (whole exome sequencing, WES) has developed into a successful diagnostic method for identify- ing the cause of the problem. It is not yet clear, however, when WES should best be used in routine clinical practice in order to exploit the potential of this method to the fullest. METHODS: In an interdisciplinary study, we carried out standardized clinical pheno- typing and a systematic genetic analysis (WES of the index patient and his or her parents, so-called trio WES) in 50 children with developmental disturbances of unclear etiology and with nonspecific neurological manifestations. RESULTS: In 21 children (42% of the collective), we were able to identify the cause of the disorder by demonstrating a mutation in a gene known to be associated with disease. Three of these children subsequently underwent specific treatment. In 22 other children (44%), we detected possibly etiological changes in candidate genes not currently known to be associated with human disease. CONCLUSION: Our detection rate of at least 42% is high in comparison with the results obtained in other studies from Germany and other countries to date and implies that WES can be used to good effect as a differential diagnostic tool in pediatric neurol- ogy. WES should be carried out in both the index patient and his or her parents (trio- WES) and accompanied by close interdisciplinary collaboration of human geneti- cists and pediatricians, by comprehensive and targeted phenotyping (also after the diagnosis is established), and by the meticulous evaluation of all gene variants.
BACKGROUND: In developed countries, global developmental disorders are encounter- ed in approximately 1% of all children. The causes are manifold, and no exogenous cause can be identified in about half of the affected children. The parallel investi- gation of the coding sequences of all genes of the affected individual (whole exome sequencing, WES) has developed into a successful diagnostic method for identify- ing the cause of the problem. It is not yet clear, however, when WES should best be used in routine clinical practice in order to exploit the potential of this method to the fullest. METHODS: In an interdisciplinary study, we carried out standardized clinical pheno- typing and a systematic genetic analysis (WES of the index patient and his or her parents, so-called trio WES) in 50 children with developmental disturbances of unclear etiology and with nonspecific neurological manifestations. RESULTS: In 21 children (42% of the collective), we were able to identify the cause of the disorder by demonstrating a mutation in a gene known to be associated with disease. Three of these children subsequently underwent specific treatment. In 22 other children (44%), we detected possibly etiological changes in candidate genes not currently known to be associated with human disease. CONCLUSION: Our detection rate of at least 42% is high in comparison with the results obtained in other studies from Germany and other countries to date and implies that WES can be used to good effect as a differential diagnostic tool in pediatric neurol- ogy. WES should be carried out in both the index patient and his or her parents (trio- WES) and accompanied by close interdisciplinary collaboration of human geneti- cists and pediatricians, by comprehensive and targeted phenotyping (also after the diagnosis is established), and by the meticulous evaluation of all gene variants.
Authors: Anita Rauch; Juliane Hoyer; Sabine Guth; Christiane Zweier; Cornelia Kraus; Christian Becker; Martin Zenker; Ulrike Hüffmeier; Christian Thiel; Franz Rüschendorf; Peter Nürnberg; André Reis; Udo Trautmann Journal: Am J Med Genet A Date: 2006-10-01 Impact factor: 2.802
Authors: Xiaoxiao Zhang; Antoine Snijders; Richard Segraves; Xiuqing Zhang; Anita Niebuhr; Donna Albertson; Huanming Yang; Joe Gray; Erik Niebuhr; Lars Bolund; Dan Pinkel Journal: Am J Hum Genet Date: 2005-01-04 Impact factor: 11.025
Authors: Vandana Shashi; Allyn McConkie-Rosell; Bruce Rosell; Kelly Schoch; Kasturi Vellore; Marie McDonald; Yong-Hui Jiang; Pingxing Xie; Anna Need; David B Goldstein; David G Goldstein Journal: Genet Med Date: 2013-08-29 Impact factor: 8.822
Authors: Robert C Green; Jonathan S Berg; Wayne W Grody; Sarah S Kalia; Bruce R Korf; Christa L Martin; Amy L McGuire; Robert L Nussbaum; Julianne M O'Daniel; Kelly E Ormond; Heidi L Rehm; Michael S Watson; Marc S Williams; Leslie G Biesecker Journal: Genet Med Date: 2013-06-20 Impact factor: 8.822
Authors: Sebastian Köhler; Sandra C Doelken; Christopher J Mungall; Sebastian Bauer; Helen V Firth; Isabelle Bailleul-Forestier; Graeme C M Black; Danielle L Brown; Michael Brudno; Jennifer Campbell; David R FitzPatrick; Janan T Eppig; Andrew P Jackson; Kathleen Freson; Marta Girdea; Ingo Helbig; Jane A Hurst; Johanna Jähn; Laird G Jackson; Anne M Kelly; David H Ledbetter; Sahar Mansour; Christa L Martin; Celia Moss; Andrew Mumford; Willem H Ouwehand; Soo-Mi Park; Erin Rooney Riggs; Richard H Scott; Sanjay Sisodiya; Steven Van Vooren; Ronald J Wapner; Andrew O M Wilkie; Caroline F Wright; Anneke T Vulto-van Silfhout; Nicole de Leeuw; Bert B A de Vries; Nicole L Washingthon; Cynthia L Smith; Monte Westerfield; Paul Schofield; Barbara J Ruef; Georgios V Gkoutos; Melissa Haendel; Damian Smedley; Suzanna E Lewis; Peter N Robinson Journal: Nucleic Acids Res Date: 2013-11-11 Impact factor: 16.971
Authors: Amelle Shillington; Martine Lamy; Kelli C Dominick; Michael Sorter; Craig A Erickson; Robert Hopkin Journal: Front Genet Date: 2022-06-13 Impact factor: 4.772